Ketorolac Tromethamine for Pancreatic Cancer

Phase-Based Progress Estimates
Cedars- Sinai Medical Center, Los Angeles, CAPancreatic Cancer+1 MoreKetorolac Tromethamine - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will see if taking ketorolac helps pancreatic cancer patients with weight and quality of life.

Eligible Conditions
  • Pancreatic Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 13 Secondary · Reporting Duration: 14 days

14 days
Evaluate change in physical function from baseline through the End-of Study visit
Evaluate change in quality of life including pain assessment from baseline through the End-of-Study visit
Mean change in average heart rate from baseline
Mean change in body fat from baseline through the End-of-Study visit
Mean change in daily active minutes from baseline
Mean change in daily activity (step taken) from baseline
Mean change in peak heart rate from baseline
Mean change in sleep disturbances from baseline
Mean change in sleep duration from baseline
Mean change in weight from baseline through the End-of-Study visit
To describe the adverse events associated with ketorolac when administered.
6 days
Decrease in inflammatory biomarkers (CA-19 and CRP) from baseline
Feasibility determined by the number of patients that take the prescribed dose of ketorolac (4 times daily) for 5 consecutive days.
Mean change in calories consumed from baseline through the End-of-Treatment visit

Trial Safety

Trial Design

1 Treatment Group

Ketorolac (open label)
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Ketorolac Tromethamine · No Placebo Group · Phase < 1

Ketorolac (open label)
Experimental Group · 1 Intervention: Ketorolac Tromethamine · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketorolac Tromethamine
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days

Who is running the clinical trial?

Andrew Hendifar, MDLead Sponsor
5 Previous Clinical Trials
93 Total Patients Enrolled
Yinuoke Ltd.UNKNOWN

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have advanced and difficult-to-treat pancreatic cancer and have been referred to Cedars-Sinai Medical Center for treatment.

Frequently Asked Questions

How many participants are currently engaged in this trial?

"Affirmative. According to, the recruitment process for this medical trial is still going on and began on July 1st 2022, with a recent update being posted on July 15th of that same year. The team needs 20 individuals at one location to partake in their research." - Anonymous Online Contributor

Unverified Answer

Are there still available positions for those interested in contributing to this research?

"Currently, the clinical trial is open to recruitment as declared on; its initial posting was July 1st 2022 and it was last updated two weeks later on July 15th." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.